Loading...
NPI 1992740856 · Riverhead, NY · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Alexander Zuhoski is a hematology & oncology physician provider located in Riverhead, New York. This profile covers 120 Medicare and 17 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Alexander Zuhoski |
| Address | 750 Old Country Road Building 2 |
| City | Riverhead |
| State | NY |
| ZIP | 11901 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | June 17, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.4M |
| Medicaid | $45.7K |
This provider is overwhelmingly Medicare-facing: lifetime Medicare revenue is $4.4M compared with $45.7K in Medicaid, making Medicare the dominant payer by a wide margin and indicating the practice’s financial scale and negotiating exposure are primarily tied to Medicare reimbursement. Medicaid appears to be a very small share of overall volume, effectively making the provider a Medicare-focused operation.
Medicare revenue is concentrated in a small set of high-cost injectable drugs: the top three Medicare codes (J9271, J2796, J9144) account for 50.9% of Medicare revenue, with J9271 reported as $1.1M (26.3%), J2796 $606.6K (14.9%), and J9144 $396.7K (9.7%). This concentration signals material reliance on specialty oncology/hematology pharmaceuticals rather than procedure fees alone.
The code mix and high volumes of infusible agents and related administration and lab codes point to an infusion-centric hematology/oncology practice model. High-revenue drugs such as J9271 (pembrolizumab) and J9144 (daratumumab) along with infusion/chemotherapy administration codes (e.g., 96413, 96365) and specialty lab testing (88185, 88184, 83521) are consistent with on-site infusion services, complex cancer/hematology management, and in-house diagnostic support.
The provider exhibits unusually high national standing on several specific codes, suggesting pockets of exceptional volume: J2796 ranks #1 of 20 providers nationally (100th percentile; notably above typical national volume for this code), and J1439 ranks #10 of 1209 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code). At the same time many chemotherapy and lab codes sit in typical to high percentiles, indicating a mix of niche national leadership in specific biologic therapies alongside more common infusion and lab activity.
Office visit and chronic care management billing to Medicare is also substantial and unusually concentrated: 99214 produced 2.8K claims and $315.3K (7.7% of Medicare revenue) and ranks #365 of 479517 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), while 99490 generated $95.2K (2.3%). These patterns suggest significant longitudinal patient management and frequent, higher-intensity E/M encounters in the Medicare population in addition to infusion care.
Medicaid revenue is highly concentrated in a narrow set of codes: the top three Medicaid codes (99214, 99490, 85025) account for 95.5% of Medicaid revenue, with 99214 alone accounting for $35.5K (77.7%). However, Medicaid volume is small in absolute terms, so while office visits drive the Medicaid portfolio, the overall Medicaid footprint remains modest relative to Medicare.
There is a pronounced payer-level reimbursement differential on the same encounters: 99214 appears in both payers but with very different scale and average payments (Medicare 99214 shows 2.8K claims, $114 avg paid/claim, $315.3K revenue and is an extreme outlier nationally, while Medicaid 99214 shows 1.7K claims, $21 avg paid/claim, $35.5K revenue and ranks as typical in-state). This underscores that the provider’s clinical workload spans payers but is monetized much more heavily through Medicare rates and volume.
The provider has long tenure in claims data (NPI enumerated 2006-06-17 (~20 years ago)), supporting the interpretation that these billing patterns represent an established practice rather than a short-term or transitional billing profile. Combined with high national ranks on specific biologic and infusion codes, the tenure suggests an entrenched hematology/oncology infusion practice with specialized prescribing patterns (notably for romiplostim, pembrolizumab, and daratumumab).
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
120 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 25,000 | $40 | $1.1M |
| J2796 | Injection, romiplostim, 10 micrograms | 8,310 | $70 | $606.6K |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 10,440 | $40 | $396.7K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 2,770 | $110 | $315.3K |
| J0897 | Injection, denosumab, 1 mg | 14,640 | $20 | $263.5K |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 7,190 | $30 | $237.3K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 180,000 | $1 | $180K |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 7,630 | $20 | $175.5K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 1,060 | $160 | $172.9K |
| 99490 | The clinical staff provides services directed by the provider to support and coordinate a patient’s care across multiple disciplines. The patient has two or more chronic conditions that place the… | 1,730 | $60 | $95.2K |
Showing 1–10 of 120
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 120 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
120 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 4 | 60 | 9,900 | $40 | $505.5K |
| J9144 | 12 | 20 | 10,440 | $40 | $499.4K |
| J2796 | 1 | 10 | 1,950 | $70 | $226.1K |
| J1568 | 2 | 30 | 2,880 | $30 | $113.4K |
| J0897 | 19 | 490 | 2,820 | $20 | $84.4K |
| 88185 | 11 | 100 | 1,210 | $20 | $74.9K |
| Q5123 | 2 | 10 | 1,820 | $30 | $62.1K |
| J1439 | 1 | 90 | 39,750 | $1 | $42K |
| J0881 | 12 | 80 | 13,100 | $1 | $41K |
| 86769 | 41 | 50 | 180 | $40 | $32.3K |
Showing 1–10 of 120
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,690 | $20 | $35.5K |
| 99490 | The clinical staff provides services directed by the provider to support and coordinate a patient’s care across multiple disciplines. The patient has two or more chronic conditions that place the… | 930 | $10 | $5.6K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 2,560 | $1 | $2.6K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 830 | $1 | $1.7K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 30 | $10 | $210 |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 70 | $1 | $130 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 70 | $1 | $70 |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 2,140 | $0 | $0 |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 1,420 | $0 | $0 |
| 82607 | The lab analyst performs a test to measure the amount of vitamin B12 in a patient specimen, typically in patient blood. | 30 | $0 | $0 |
Showing 1–10 of 17
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
17 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 352 | 430 | 680 | $120 | $299.9K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 285 | 590 | 1,160 | $20 | $277.2K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 2,811 | 16,550 | 220 | $90 | $186.8K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 1,548 | 2,050 | 90 | $140 | $121.2K |
| 82607 | The lab analyst performs a test to measure the amount of vitamin B12 in a patient specimen, typically in patient blood. | 309 | 350 | 1,020 | $10 | $54.3K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 489 | 1,420 | 300 | $20 | $38.8K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 322 | 850 | 960 | $1 | $36.4K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 1,190 | 5,090 | 450 | $10 | $35.9K |
| 82728 | The lab analyst measures the level of ferritin, an important protein composed of about 20 percent iron. Ferritin also acts as an iron reserve in the body, and is present in serum in only minute… | 251 | 390 | 730 | $10 | $34.6K |
| 83540 | The lab analyst measures the iron level, primarily in serum. Iron is one of the essential elements in the body, and the greatest portion is present combined with hemoglobin within the red blood cells. | 223 | 340 | 670 | $1 | $16.2K |
Showing 1–10 of 17
Other providers in the same ZIP code as Alexander Zuhoski, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Suffolk Primary Health, LLC | NY | Primary Care Clinic/Center | $0 | $22.3M |
| Deepali Sharma | NY | Hematology & Oncology Physician | $2.6M | $57.1K |
| Paul Youn | NY | Radiation Oncology Physician | $2.3M | $0 |
| Yelda Nouri | NY | Hematology & Oncology Physician | $1.8M | $49.1K |
| Neal Murphy | NY | Hematology & Oncology Physician | $1.1M | $9.8K |
| Rajoo Patel | NY | Cardiovascular Disease Physician | $1.1M | $6.6K |
| Roy Prashad | NY | Rheumatology Physician | $1.1M | $700 |
| Isamettin Aral | NY | Radiation Oncology Physician | $1M | $0 |
| Mitchell Meyerson | NY | Specialist | $819.6K | $0 |
| Scott Sheren | NY | Ophthalmology Physician | $818.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.